Infant Bacterial Therapeutics AB (publ)

IBT-B · Nasdaq Stockholm · Healthcare

69.50SEK −0.6%last day

Price as of 2 October 2026

The price over the past year, with dividends: +2.1%

Performance

1 month

+7.1%

1 year

+2.1%

3 years, per year

−6.3%

5 years, per year

−2.5%

Largest fall, 3 years

−74.6%

Below the peak now

−73.9%

Volatility, 1 year

53.4%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

17.0

Dividend yield

0.0%

Return on equity

−154.5%

Net margin

–

Market value

93 m USD

Quality, value and trend

Where Infant Bacterial Therapeutics stands against every Nordic stock today. 100 is best.

Quality30

Profitability and a sound balance sheet over time. Better than 30% of Nordic stocks.

Value2

The price measured against earnings, assets and cash flow. Better than 2% of Nordic stocks.

Trend71

The price development over the past year. Better than 71% of Nordic stocks.

Combined20

Quality, value and trend together. Better than 20% of Nordic stocks.

About Infant Bacterial Therapeutics

Infant Bacterial Therapeutics AB (publ) is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 6 employees.

Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which has completed Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis